» Articles » PMID: 38254286

Progressive, Multi-organ, and Multi-layered Nature of Cancer Cachexia

Overview
Journal Cancer Sci
Specialty Oncology
Date 2024 Jan 23
PMID 38254286
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer cachexia is a complex, multifaceted condition that negatively impacts the health, treatment efficacy, and economic status of cancer patients. The management of cancer cachexia is an essential clinical need. Cancer cachexia is currently defined mainly according to the severity of weight loss and sarcopenia (i.e., macrosymptoms). However, such macrosymptoms may be insufficient to give clinicians clues on how to manage this condition as these symptoms appear at the late stage of cancer. We need to understand earlier events during the progression of cancer cachexia so as not to miss a clinical opportunity to control this complex syndrome. Recent research indicates that cancer-induced changes in the host are much wider than previously recognized, including disruption of liver function and the immune system. Furthermore, such changes are observed before the occurrence of visible distant metastases (i.e., in early, localized cancers). In light of these findings, we propose to expand the definition of cancer cachexia to include all cancer-induced changes to host physiology, including changes caused by early, localized cancers. This new definition of cancer cachexia can provide a new perspective on this topic, which can stimulate the research and development of novel cancer cachexia therapies.

Citing Articles

Intra-Tumoral Lymphocytic Infiltration Is Associated with Favorable Prognosis in Suboptimal Surgery in High-Grade Serous Ovarian Carcinoma.

Harada H, Hachisuga T, Harada Y, Shibahara M, Murakami M, Nuratdinova F Diagnostics (Basel). 2025; 15(4).

PMID: 40002574 PMC: 11854212. DOI: 10.3390/diagnostics15040422.


Convergent inducers and effectors of T cell paralysis in the tumour microenvironment.

Hanahan D, Michielin O, Pittet M Nat Rev Cancer. 2024; 25(1):41-58.

PMID: 39448877 DOI: 10.1038/s41568-024-00761-z.


Progressive, multi-organ, and multi-layered nature of cancer cachexia.

Nakamura Y, Saldajeno D, Kawaguchi K, Kawaoka S Cancer Sci. 2024; 115(3):715-722.

PMID: 38254286 PMC: 10921013. DOI: 10.1111/cas.16078.

References
1.
Ding G, Xiang X, Hu Y, Xiao G, Chen Y, Binari R . Coordination of tumor growth and host wasting by tumor-derived Upd3. Cell Rep. 2021; 36(7):109553. PMC: 8410949. DOI: 10.1016/j.celrep.2021.109553. View

2.
Galvao D, Taaffe D, Spry N, Cormie P, Joseph D, Chambers S . Exercise Preserves Physical Function in Prostate Cancer Patients with Bone Metastases. Med Sci Sports Exerc. 2017; 50(3):393-399. PMC: 5828380. DOI: 10.1249/MSS.0000000000001454. View

3.
Beltra M, Pollanen N, Fornelli C, Tonttila K, Hsu M, Zampieri S . NAD repletion with niacin counteracts cancer cachexia. Nat Commun. 2023; 14(1):1849. PMC: 10070388. DOI: 10.1038/s41467-023-37595-6. View

4.
Allen B, Hiam K, Burnett C, Venida A, DeBarge R, Tenvooren I . Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat Med. 2020; 26(7):1125-1134. PMC: 7384250. DOI: 10.1038/s41591-020-0892-6. View

5.
Emmerson P, Wang F, Du Y, Liu Q, Pickard R, Gonciarz M . The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat Med. 2017; 23(10):1215-1219. DOI: 10.1038/nm.4393. View